| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Strong antiproliferative action against 3LL and RMS-J1 tumor cells is demonstrated by SIBA (0.5 mM; 24-96 h) [1]. In HEp2 cells infected with HSV-1, SIBA (1 mM; 12, 24 hours) reversibly reduces HSV production [2]. After ten hours, SIBA reduced the amount of protein synthesis infected with HSV-1 in HEp2 cells by 98% [2]. In HEp2 cells infected with HSV-1, SIBA (1 mM; 8.5 hours) suppresses RNA methylation and protein production [2]. SIBA (0.5, 1.0 mM; 24, 48 hours) interferes with polyamine production, possibly by blocking aminopropyltransferase, and reversibly inhibits the conversion of putrescine to spermidine and/or spermine[3].
|
|---|---|
| ln Vivo |
Tumor growth is inhibited in vivo by SIBA (150 mg/kg; intraperitoneal injection; twice weekly for 3 weeks) [1]. In vivo, SIBA (15 mg/kg; intraperitoneal injection; three times a week for four weeks) prevents RMS-J1 cells from spreading metastatically [1].
|
| Cell Assay |
Cell proliferation assay [1]
Cell Types: 3 LL and RMS-J1 Cell Tested Concentrations: 0.5 mM Incubation Duration: 24-96 hrs (hours) Experimental Results: Effectively inhibited the growth of 3LL and RMS-J1 tumor cells by 96% and 88%, respectively. Cell viability assay [2] Cell Types: HEp2 cells (HSV-1 infection) Tested Concentrations: 1 mM Incubation Duration: 12, 24 hrs (hours) Experimental Results: At 12 hrs (hours) and 24 hrs (hours), virus production was diminished by 88.4% and 98.2%, respectively. Cell viability assay [2] Cell Types: HEp2 cells (HSV-1 infection) Tested Concentrations: 1 mM Incubation Duration: 8.5 hrs (hours) Experimental Results: Protein synthesis diminished by 41.3% in normal medium and 63.5% in medium lacking methionine %. Inhibits RNA methylation by 65.4%. Cell viability assay [3] Cell Types: Chicken embryo fibroblasts Tested Concentrations: 0.5, 1.0 mM Incubation Duration: 24, 48 h Experimental Results: Inhibition of radioactive diamine uptake, and the inhibition was dose-dependent. Dramatically inhibits the formation of [14C]spermidine and [14C]spermine from [14C]putrescine. Mainly inhibits th |
| Animal Protocol |
Animal/Disease Models: C57BL/6 female mice (4-8 weeks old) [1].
Doses: 150 mg/kg Route of Administration: intraperitoneal (ip) injection; twice a week for 3 weeks. Experimental Results: The median number of lung metastases was Dramatically diminished. Animal/Disease Models: Adult syngeneic Wistar AG rats (8 weeks old; subcutaneously (sc) (sc) transplanted with RMS-J1 cells) [1]. Doses: 15 mg/kg Route of Administration: intraperitoneal (ip) injection; three times a week for 4 weeks. Experimental Results: Inhibiting the metastasis and spread of RMS-J1 cells in vivo, the median number of lung metastasis nodules was 26. |
| References |
|
| Molecular Formula |
C14H21N5O3S
|
|---|---|
| Molecular Weight |
339.41324
|
| Exact Mass |
339.137
|
| CAS # |
35899-54-8
|
| PubChem CID |
123674
|
| Appearance |
Off-white to gray solid powder
|
| LogP |
0.998
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
405
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(C)CSC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
|
| InChi Key |
JDDUQGRUPLKDNT-IDTAVKCVSA-N
|
| InChi Code |
InChI=1S/C14H21N5O3S/c1-7(2)3-23-4-8-10(20)11(21)14(22-8)19-6-18-9-12(15)16-5-17-13(9)19/h5-8,10-11,14,20-21H,3-4H2,1-2H3,(H2,15,16,17)/t8-,10-,11-,14-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-(2-methylpropylsulfanylmethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~294.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9463 mL | 14.7314 mL | 29.4629 mL | |
| 5 mM | 0.5893 mL | 2.9463 mL | 5.8926 mL | |
| 10 mM | 0.2946 mL | 1.4731 mL | 2.9463 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
